Skip to content

Reducing Nephrotoxicity of Vancomycin: A Prospective Study of Continuous Versus Intermittent Infusion of Vancomycin

Reducing Nephrotoxicity of Vancomycin: A Prospective, Randomized Study of Continuous Versus Intermittent Infusion of Vancomycin

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01720940
Enrollment
220
Registered
2012-11-02
Start date
2012-10-31
Completion date
2015-09-30
Last updated
2012-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections Requiring Prolonged Duration (>10 Days) of Vancomycin

Brief summary

This study is being carried out to find out whether there is reduction in vancomycin-induced kidney injury (nephrotoxicity) when vancomycin is given as intermittent versus continuous infusion. This study will recruit 220 subjects from 2 hospitals over a period of 3 years. Participants are invited if they have an infection that requires prolonged vancomycin therapy (\> more than 10 days).

Interventions

24-hour continuous infusion of vancomycin

DRUGintermittent vancomycin infusion

Sponsors

Tan Tock Seng Hospital
CollaboratorOTHER
National University Hospital, Singapore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Adults aged 21-80 years * Documented infection requiring prolonged (\> 10 days) of vancomycin therapy * Creatinine clearance \> 50 ml/min (using Cockroft-Gault equation)

Exclusion criteria

* Patient already received 7 days or more of vancomycin therapy * Pregnancy * Severe burns \> 40% body surface area * Spinal cord injuries * Participation in another interventional trial in previous 30 days * Inability to obtain informed consent

Design outcomes

Primary

MeasureTime frameDescription
nephrotoxicityoccurring any time while on vancomycin treatment up to 14 days post treatment completionnephrotoxicity as defined by the acute kidney injury network (AKIN) criteria using only serum creatinine criteria

Secondary

MeasureTime frameDescription
biomarkers for detection of early nephrotoxicitymeasured weekly from the date of randomization until 14 days post completion of vancomycinserum and urine NGAL and cystatin C

Countries

Singapore

Contacts

Primary ContactShire Yang Tan
shire_yang_tan@nuhs.edu.sg97989001

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026